Top Biotech Companies in Melbourne (22)
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
Analytical scientists and clinical researchers worldwide rely on Agilent to help fulfill their most complex laboratory demands. Our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. Whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or...
Agilent Technologies's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry and company materials consistently place Agilent among the top global players in analytical instrumentation—especially in chromatography and mass spectrometry—and as a frequent short‑list vendor for regulated and R&D labs. Recognition such as Instrument Business Outlook’s “Company of the Year” supports this standing.
Diversified Revenue Streams: The portfolio spans instruments, software/informatics, consumables, and services (Agilent CrossLab), with end‑to‑end workflows and specialty CDMO contributions providing multiple revenue levers. This breadth increases switching costs and drives recurring revenue that helps balance capital‑equipment cycles.
Resilient & Sustainable Growth: After a FY2024 decline, revenue returned to growth in FY2025 and continued in Q1 FY2026, with guidance pointing to mid‑single‑digit core growth and margin expansion. CrossLab’s steady growth and an instrument replacement cycle are cited as continuing supports.
PolyNovo is a disruptive ASX 200 medical technology company. Its products simplify managing acute complex wounds, redefining healing with differentiated outcomes across many etiologies. After treating 62,000+ patients across 46 countries, the company is investing for growth via new products, indications and markets with a view to treat millions more. Our registered address is 2/320 Lorimer St, Port Melbourne, Victoria...
BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina’s Research Triangle Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of therapeutics across...
The brain is central to every aspect of our lives, yet it isn’t monitored with the same consistency and proactivity as other vital signs. As a neuroscience technology company, we believe that better brain health insights lead to better brain health outcomes. That's why we're on a mission to democratize cognitive health by radically simplifying the way it is measured. For...
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to...
Amgen's Top Stability & Growth Strengths
Strong Revenue Growth: 2025 results show total revenues up 10% to $36.8 billion and guidance for 2026 at $37.0–$38.4 billion signals continued top‑line expansion.
Diversified Revenue Streams: Company updates indicate a broad base with roughly 40 marketed products and 14 blockbusters in 2024, and in 2025 eighteen products reached record sales with notable growth from Repatha, TEZSPIRE, EVENITY, BLINCYTO, and rare‑disease brands.
Strong Market Position & Advantage: Evidence suggests Amgen is widely regarded as a leader among large‑cap biotechs with significant scale and an expanded rare‑disease footprint following the Horizon acquisition.
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to...
Moderna's Top Stability & Growth Strengths
Innovation-Driven Growth: The company is positioned as a leader in mRNA medicine with multiple late-stage respiratory and oncology programs that could expand beyond COVID into new indications. Acceptance of the flu BLA and positive Phase 3 data for a flu+COVID combo create concrete approval catalysts that could broaden the seasonal franchise if reviews are favorable.
Product Line Growth: The business is transitioning from a single declining product toward a multi-product portfolio, with RSV, next-gen COVID, flu, and combo vaccines advancing toward targeted 2026 approvals. Management’s expectation of modest revenue growth in 2026, with no flu or flu/COVID revenue assumed, implies potential upside if launches land on time.
Strong Market Position & Advantage: The company has demonstrated platform leadership by scaling mRNA globally during COVID and securing a non-COVID mRNA vaccine approval with mRESVIA, including a label expansion to certain higher-risk adults. Settlement of the lipid-nanoparticle patent dispute removes a major legal overhang, improving focus and visibility for launches and late-stage execution.
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com. Together with...
Stryker's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show double-digit annual sales expansion through 2025, with management guiding to continued organic growth into 2026.
Strong Market Position & Advantage: Evidence highlights leadership in orthopedic robotics and top-tier standings among global medtech peers, with notable share in joint replacement and integrated OR technologies.
Diversified Revenue Streams: Multiple segments and recent vascular-focused acquisitions broaden growth drivers and reduce reliance on any single category.
PolyActiva is an innovative clinical-stage ophthalmology company with a unique proprietary polymeric prodrug technology that enables site-specific, precise and controlled drug delivery to the eye. With the PolyActiva technology, exceptional zero-order release profiles are achieved over treatment periods ranging from 6 to 12 months. Our mission is to become a leader in ophthalmic medicine by providing unique biodegradable implants with...
Planet Pharma was founded by a dedicated team of seasoned professionals with extensive experience supporting the pharmaceutical, biotechnology and device industries. Our goal was to create an organization that strengthens the employer-employee dynamic by connecting clients with talent — ultimately making staffing more personal and creating enduring, valuable relationships. We are able to achieve this by leveraging cutting-edge technology and flexible...
Nutromics is an Australian-born diagnostic company with a vision to create a world with zero preventable deaths due to a lack of continuous diagnostic monitoring. The Nutromics patch consists of DNA-based sensors coated onto the tips of microneedles. Our breakthrough technology unlocks continuous and real-time monitoring of multiple clinically relevant targets for some of the deadliest disease states in the...
Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe,...
PPD is now part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and PPD are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We now offer a comprehensive suite of world-class services across the clinical development spectrum – from...
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to...
QIAGEN's Top Stability & Growth Strengths
Strong Market Position & Advantage: Leadership in latent TB blood testing (QuantiFERON) and entrenched sample‑preparation technologies is reinforced by global guidelines and deep workflow stickiness. The company is also building share in digital PCR and competes credibly in syndromic panels despite strong incumbents.
Resilient & Sustainable Growth: Net sales grew in 2025 with guidance for further mid‑single‑digit growth in 2026, and earnings are guided to improve. Growth is increasingly driven by non‑COVID ‘pillars’ with recurring consumables and software that generally support steadier demand.
Future-Ready Strategy: Management pruned non‑core lines (e.g., NeuMoDx exit) and refocused investment on five growth pillars with multi‑year targets through 2028. Ongoing menu expansions, regulatory submissions, and targeted M&A (e.g., single‑cell and clinical genomics software) indicate continued positioning for scaled, profitable growth.
Novotech is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, "Novotech" and "PPC". Novotech is a full-service clinical CRO with labs, phase I facilities, and drug development consulting services.
The Atmo Gas Capsule is a world first patented solution to accurately profile the gases within the gut, leading to better diagnosis and treatment of gastrointestinal disorders.
CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring,...
Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience.
Natural MedTech is manufacturing psychedelic medicines to unlock neurologic potential. We are building Australia’s leading pure-play psychedelic business, with differentiated IP, an experienced team, and a self-funding growth profile.
